Except for more frequent use of SGLT2 inhibitors in patients with less extensive A-Pd reduction (7% vs. 20%, p = 0.03), there were no significant differences regarding heart failure medication (see Table 1). The gene discussed is SLC5A2; the disease is heart failure.